Best of ASCO - 2014 Annual Meeting

 

Welcome

Advanced Disease

Gastrointestinal (Colorectal) Cancer

2018 ASCO Annual Meeting

Sort by: title abstract no. first author
ABSTRACT TITLEFIRST AUTHORABSTRACT NO.
5-fluorouracil plus bevacizumab plus anakinra for patients with metastatic colorectal cancer refractory to standard therapies (IRAFU): An investigator-initiated, open-label, single-arm, multicentre, phase 2 study.

Nicolas Isambert

e15540

A meta-analysis exploring the role of PET and PET-CT in the management of potentially resectable colorectal cancer liver metastasis.

Julian Daza Vargas

3547

A novel biomarker combination and its association with resistance to chemotherapy combinations with bevacizumab: First results of the PERMAD trial.

Thomas Seufferlein

e15545

A phase I expansion study of trifluridine and tipiracil (FTD/TPI) in combination with irinotecan (IRI) and bevacizumab (BEV) in patients with metastatic colorectal cancer (mCRC).

Anna M. Varghese

3546

A phase I/II study of nintedanib and capecitabine in refractory metastatic colorectal cancer.

Patrick McKay Boland

3552

A phase I/II trial of cabozantinib (C) with or without panitumumab (P) in patients (pts) with RAS wild-type (WT) metastatic colorectal cancer (mCRC): Clinical outcomes in pts with MET amplification (amp) detected in blood.

Jingquan Jia

3555

A pilot study of omalizumab to reduce the incidence of oxaliplatin-induced hypersensitivity reaction (HSR): An interim analysis.

Stacey Stein

e15555

A prospective multicenter observational study of bevacizumab for the treatment of metastatic colorectal cancer in Chinese patients (Obtain study).

Fenghua Wang

e15560

A prospective phase II study of raltitrexed combined with S-1 as salvage treatment for patients with metastatic colorectal cancer after failure of standard chemotherapy.

Mingzhu Huang

e15558

A randomized phase II study of perioperative chemotherapy plus bevacizumab versus postoperative chemotherapy plus bevacizumab inpatients with upfront resectable hepatic colorectal metastases (APPROACH).

You Jin Chun

3528

A randomized phase II study of trastuzumab and pertuzumab (TP) compared to cetuximab and irinotecan (CETIRI) in advanced/metastatic colorectal cancer (mCRC) with HER2 amplification: S1613.

Kanwal Pratap Singh Raghav

TPS3620

A validation study of stratification by the 55-gene classifier for assessing recurrence risk in stage II colon cancer: The 55 STAR study (UMIN23879).

Shigeki Yamaguchi

3526

ABT-165 plus FOLFIRI vs bevacizumab (bev) plus FOLFIRI in patients (pts) with metastatic colorectal cancer (mCRC) previously treated with fluoropyrimidine/oxaliplatin and bev.

Zev A. Wainberg

TPS3619

Actionable fusions in colorectal cancer using a cell-free circulating tumor DNA (ctDNA) assay.

Katherine Clifton

3507

Adding oxaliplatin (OX) to neoadjuvant therapy of locally advanced rectal cancer (LARC): Still a promising option?

Wojciech Rogowski

e15570

Analysis of liquid biopsies from metastatic colorectal carcinoma (mCRC) patients (pts) enrolled in the ERMES clinical trial.

Nicola Normanno

e15507

Anti-EGFR resistant clones decay exponentially after progression: Implications for anti-EGFR rechallenge.

Christine Megerdichian Parseghian

3511

Apatinib as a salvage treatment for refractory metastatic colorectal cancer.

Xiaofeng Chen

3556

APOLLON: A phase I/II study of panitumumab combined with TAS-102 in patients (pts) with RAS wild-type (wt) metastatic colorectal cancer (mCRC).

Yasutoshi Kuboki

3523

Association between genotypes, clinical scores and survival outcome in metastatic colorectal cancer.

Moreno Reinaldo

3553

Avelumab and cetuximab in combination with FOLFOX in patients with previously untreated metastatic colorectal cancer (MCRC): Results of the safety run-in phase of the phase II AVETUX trial (AIO-KRK-0216).

Alexander Stein

3561

Bevacizumab (B) + bi-weekly capecitabine (C) and oxaliplatin (O) (XELOX2) or FOLFOX4 in first-line treatment of metastatic colorectal cancer (mCRC): Final results of a multicenter randomized phase II trial of the Gruppo Oncologico dell’Italia Meridionale (GOIM protocol 2802).

Evaristo Maiello

3542

BRAF (V600E) mutant metastatic colorectal cancer: What is the role of the antiangiogenic therapy in a real-world setting?

Nieves Martinez Lago

e15561

Can machine learning predict resecability of a peritoneal carcinomatosis.

Alexandre Maubert

e15543

Change in CEA as an early predictor of progression to first-line systemic therapy in metastatic colorectal cancer.

Pat Gulhati

3525

Circulating tumor DNA (ctDNA) as an early marker to monitor clinical benefit of regorafenib and TAS-102 in patients with metastatic colorectal cancer (mCRC).

Allan Andresson Lima Pereira

3533

Circulating vitamin D during neoadjuvant therapy in high-risk rectal cancer.

Hanna Abrahamsson

e15532

Clinical and molecular determinants of extrahepatic disease progression (ePD) in initially unresectable, liver limited metastatic colorectal cancer (mCRC).

Elena Ongaro

e15511

Colorectal Cancer Metastatic dMMR Immuno-Therapy (COMMIT) study (NRG- GI004/SWOG-S1610): A randomized phase III study of mFOLFOX6/bevacizumab combination chemotherapy with or without atezolizumab or atezolizumab monotherapy in the first-line treatment of patients with deficient DNA mismatch repair (dMMR) metastatic colorectal cancer.

James J. Lee

TPS3615

Comparison of mismatch repair status between primary and matched metastatic sites in patients with colorectal cancer.

Wen-Zhuo He

3563

Correlation of measurements of tumor heterogeneity based on next-generation sequencing (NGS) of circulating tumor DNA (ctDNA) with clinical outcomes in STEAM, a prospective, randomized, multicenter study in metastatic colorectal cancer (mCRC).

Stephanie Yaung

3545

Correlation of MLLT3 deletion mutation with response to neoadjuvant chemoradiotherapy in locally advanced rectal cancer patients identified by whole-exome sequencing.

Rong-xin Zhang

e15549

Dissecting the prognostic role of sidedness in metastatic colon cancer (mCC): Retrospective analysis of the impact of chemotherapy sequence (CTS) and primary site resection (PTR) in a health care system.

Feng-Che Kuan

e15502

Distinct impacts of KRAS, NRAS and BRAF mutations on survival of patients with metastatic colorectal cancer.

Yucai Wang

3513

Dynamic monitoring of driver gene mutation profiles in plasma cfDNA using an 85 gene panel for postoperative prognosis in colorectal cancer.

Tanxiao Huang

e15536

Effect of different chemotherapy regimens on pathological response in the preoperative combined chemo radiotherapy of rectal adenocarcinomas: A retrospective analysis.

Rebecca Buecker

e15564

Effect of liver metastasis from primary rectal adenocarcinoma on activity of tissue plasminogen activators and α2-macroglobulin.

Elena Alekseevna Dzhenkova

e15552

Effect of matched therapy in metastatic colorectal cancer on progression free survival in the phase I setting.

Michael Lam

3522

Effect of PET-CT on disease recurrence and its management in patients with potentially resectable colorectal cancer liver metastases. The long-term results of a randomized controlled trial (PET-CT Imaging prior to liver resection for colorectal adenocarcinoma metastases).

Pablo Emilio Serrano Aybar

3527

Effect of time to resection of colorectal liver metastases on recurrence risk.

Emerson Yu-sheng Chen

3541

Efficacy, tolerability, and manageability of TAS-102 plus bevacizumab for metastatic colorectal cancer patients in clinical practice.

Hideki Ishikawa

e15535

Efficiency and safety of regorafenib in metastatic colorectal cancer (mCRC): Real life experience from Turkey.

Guliz Zengin

e15551

EGFR protein expression of the metastatic colorectal cancer as a prognostic/predictive factor for anti-EGFR antibody therapy.

Jozsef Timar

e15548

ENCORE 601: A phase 2 study of entinostat in combination with pembrolizumab in patients with microsatellite stable metastatic colorectal cancer.

Nilofer Saba Azad

3557

EORTC-ESSO 1409 GITCG: A prospective colorectal liver metastasis database with an integrated quality assurance program (CLIMB).

Carmela Aves Caballero

3558

Ex vivo co-culture models for immunotherapy with patient-derived tumor infiltrating lymphocytes, peripheral blood mononuclear cells and autologous patient colorectal cancer (CRC) cell lines.

Si Qi Tan

e15531

Final overall survival (OS) analysis of first-line (1L) FOLFOX-4 ± cetuximab (cet) in patients (pts) with RAS wild-type (wt) metastatic colorectal cancer (mCRC) in the phase 3 TAILOR trial.

Shukui Qin

3521

Final results of a phase II of metformin plus irinotecan for refractory colorectal cancer.

Arinilda Bragagnoli

e15527

First-in-human dose escalation of monalizumab plus durvalumab, with expansion in patients with metastatic microsatellite-stable colorectal cancer.

Neil Howard Segal

3540

First-line FOLFOX plus panitumumab (Pan) followed by 5FU/LV plus Pan or single-agent Pan as maintenance therapy in patients with RAS wild-type metastatic colorectal cancer (mCRC): The VALENTINO study.

Filippo Pietrantonio

3505

First-line treatment with panitumumab plus FOLFIRI in elderly patients with RAS/BRAF wild-type unresectable metastatic colorectal cancer and good performance status: OPALO trial.

Jaime Feliu

TPS3618

Folate gene prediction of treatment response to 5-FU and leucovorin in advanced colorectal cancer.

Bengt Gustavsson

3550

FOLFIRINOX plus cetuximab (CET) or bevacizumab (BEV) in patients (pts) with initially unresectable colorectal liver metastases (CRLM) with BRAF mutated (mut) tumors: A subgroup analysis of the UNICANCER PRODIGE 14-ACCORD 21 (METHEP2) trial.

Evelyne Lopez-Crapez

3548

Genomic landscape, clinical characteristics and outcomes of early onset (EO) compared with average onset (AO) colorectal cancer (CRC).

Gustavo Dos Santos Fernandes

3520

Genotype-driven dosing of irinotecan and adverse events in patients receiving irinotecan with UGT1A1 gene variants.

Candice Baldeo

e15544

Health related quality of life in elderly or frail patients with advanced colorectal cancer treated with dose reduced capecitabine.

Daniel Adam Breadner

3564

High levels of cell-free DNA (cfDNA) at baseline (BL) and increase of at least one mutation at day 14 (D14) as independent prognostic biomarkers for patients (pts) with advanced colorectal cancer (aCRC) under regorafenib.

Pashalina Kehagias

3532

In situ anti-cancer agent derived from [188re]rhenium nitro-imidazole ligand loaded poly-l-lysine dendrimer administrated by direct CT guided stereotactic intrahepatic injection.

Hafid Belhadj-Tahar

e15569

Identification for metastasis lymph node in magnetic resonance imaging with faster region-based convolutional neural network.

Yun Lu

e15500

Immunological effect of hydrogen gas.

Junji Akagi

e15546

Impact of modified Glasgow prognostic score and neutrophil/platelet-lymphocyte ratio on survival metastatic colorectal cancer (mCRC).

Fernando Namuche

e15557

Impact of primary tumor side on outcomes of every-2-weeks (q2w) cetuximab + first-line FOLFOX or FOLFIRI in patients with RAS wild-type (wt) metastatic colorectal cancer (mCRC) in the phase 2 APEC trial.

Timothy Jay Price

3534

Impact of the type and modalities of preoperative chemotherapy on the outcome of liver resection for colorectal liver metastases: A LiverMetSurvey study.

Yuichi Goto

3529

Implications of KRAS status in first line chemotherapy with bevacizumab in advanced colorectal cancer: A phase IV study of Hellenic Oncology Research Group (HORG).

Anna Koumarianou

e15521

Importance of maintenance of dose intensity (DI) during 1st and 2nd line chemotherapy (CT) for nonresectable metastatic colorectal cancer (mCRC).

Mikhail Fedyanin

e15523

Induction chemotherapy (CT) with FOLFIRINOX or FOLFOX/FOLFIRI, plus cetuximab (CET) or bevacizumab (BEV) (by RAS status), in patients (pts) with primarily unresectable colorectal liver metastases (CRLM): Results of the randomized UNICANCER PRODIGE 14-ACCORD 21 (METHEP-2) trial.

Marc Ychou

3535

Intensive first line FIr-C/FOx-C association of triplet chemotherapy plus cetuximab in RAS wild-type metastatic colorectal cancer patients: Preliminary phase II data and prediction of individual limiting toxicity syndromes by pharmacogenomic biomarkers.

Gemma Bruera

e15517

Ischemia-induced tumor progression after portal triad clamping in a murine model of colorectal liver metastases: Roles of TNF-a and HO-1.

Desislava Germanova

e15539

KEYNOTE-164: Pembrolizumab for patients with advanced microsatellite instability high (MSI-H) colorectal cancer.

Dung T. Le

3514

Long-term results of the ADORE trial: Adjuvant oxaliplatin, leucovorin, and 5-fluorouracil (FOLFOX) versus 5-fluorouracil and leucovorin (FL) after preoperative chemoradiotherapy and surgery for locally advanced rectal cancer.

Yong Sang Hong

3501

Maintenance treatment with capecitabine plus cetuximab (CET) for patients with RAS wild-type (wt) advanced colorectal cancer (CRC): A multi-center, phase II clinical trial.

Xianglin Yuan

e15566

Meta-analysis of KRAS mutation as prognostic factor in patients (pts.) with resection of colorectal (CRC) liver metastases: Tumor burden and sideness analysis.

Martin Angel

e15533

Metastatic colorectal cancer (mCRC) and micro-satellite instability.

Timothy Jay Price

e15510

Metastatic site of loss of oncologic control in colorectal cancer patients.

Charles Rajadurai

e15568

mFOLFOXIRI + panitumumab versus FOLFOXIRI as first-line treatment in patients with RAS wild- type metastatic colorectal cancer m(CRC): A randomized phase II VOLFI trial of the AIO (AIO- KRK0109).

Michael Geissler

3509

MiR-148a deregulation and colorectal cancer liver metastases.

Jaime Rubio Pérez

e15556

Modified FOLFOXIRI regimen as salvage treatment for metastatic colorectal cancer patients: A retrospective study.

Zhen Wang

e15571

Multicenter phase I/II trial of BBI608 and pembrolizumab combination in patients with metastatic colorectal cancer (SCOOP Study): EPOC1503.

Eiji Shinozaki

3530

Novel PET/CT imaging biomarkers of CB-839 in combination with panitumumab and irinotecan in patients with metastatic and refractory RAS wildtype (WT) colorectal cancer: A phase I/II study.

Satya Das

TPS3616

NuTide 302: A phase IB study to assess the safety, pharmacokinetics and clinical activity of NUC-3373 in combination with standard agents used in colorectal cancer treatment.

Sarah Patricia Blagden

TPS3617

Optimizing treatment strategy for advanced rectal cancer in the West and Japan: International multicenter cohort study.

Akira Ouchi

3524

Outcomes for matched patients with metastatic colitis-associated cancers versus sporadic colorectal cancer receiving chemotherapy.

Rona Yaeger

e15534

Outcomes in left versus right metastatic colorectal cancer (mCRC) in patients presenting to an inner-city safety net hospital.

Sunny R K Singh

e15542

Outcomes of cetuximab in 1st-line therapy for metastatic colorectal cancer (mCRC) according to tumor RAS/BRAF mutation (mt) status in the EREBUS cohort.

Denis Michel Smith

e15547

Outcomes of oxaliplatin-based (Ox) chemotherapy (CT) on R0 resection of colonic liver metastases (CLM).

Nicholas Adam Bosma

3538

Per protocol analysis and final OS update of the FIRE-3 (AIO KRK-0306) study comparing FOLFIRI plus cetuximab vs. FOLFIRI plus bevacizumab.

Sebastian Stintzing

3508

Phase 2 study of veliparib plus FOLFIRI ± bevacizumab versus placebo plus FOLFIRI ± bevacizumab in metastatic colorectal cancer.

Vera Gorbunova

3543

Physical activity program in patients with metastatic colorectal cancer who receive palliative first-line chemotherapy: A randomized controlled phase III trial—(ACTIVE-2 SAKK 41/14).

Viviane Hess

TPS3621

Plasma HER2 (ERBB2) copy number to predict response to HER2-targeted therapy in metastatic colorectal cancer.

Alberto Bardelli

3506

Possible predictive value of G8 score and the drug concentrations for efficacy and toxicity of trifluridine/tipiracil for elderly patients with advanced colorectal cancer: A multicenter, phase II study (T-CORE1401).

Masanobu Takahashi

e15516

Preliminary results from a study of sevacizumab in Chinese patients with metastatic colorectal cancer resistant to oxaliplatin-based first-line chemotherapy.

Nong Xu

e15530

Preventive effect of traditional Japanese medicine, syakuyakukanzoto on neurotoxicity of FOLFOX plus bevacizumab for metastatic colorectal cancer: A phase II study.

Hiroaki Takagi

e15526

Primary tumor location as a prognostic implication in patients undergoing resection for colorectal liver metastasis: A propensity score-matched analysis.

Yuichi Goto

e15504

Prognostic value of neutrophil- (NLR) and platelet-lymphocyte ratio (PLR) in patients with metastatic colorectal cancer (mCRC) with KRAS, BRAF: A Peruvian point of view.

Fernando Namuche

e15550

Proteomic profiling of phosphatidylinositol 3-kinase (PI3K) altered metastatic colorectal cancer (mCRC) after protein kinase B (Akt) inhibition: Insulin like growth factor 1 receptor (IGF1R) mediates adaptive resistance.

Maliha Nusrat

3549

Quality-adjusted time without symptoms or toxicity (Q-TWiST) of patients with metastatic colorectal cancer (mCRC) treated with fruquintinib in the randomized phase III FRESCO trial.

Yu-Xian Bai

3544

Randomized trial of irinotecan and cetuximab (IC) versus irinotecan, cetuximab and ramucirumab (ICR) as 2nd line therapy of advanced colorectal cancer (CRC) following oxaliplatin and bevacizumb based therapy: Result of E7208.

Howard S. Hochster

3504

Ranking the efficacies of FOLFOX and FOLFIRI with or without anti-EGFR therapy or bevacizumab in wild-type-RAS metastatic colorectal cancer according to primary tumor location: A network meta-analysis.

Mingyi Zhou

e15529

Real-world data on overall survival (OS) impact of anti-EGFR sequence in patients (pts) with microsatellite stable (MSS) all-RAS and BRAFV600E wild-type metastatic (met) colorectal cancer (CRC).

Elena Elez

3551

Results of a randomized phase 3 study evaluating the potential benefit of a second-look surgery plus HIPEC in patients at high risk of developing colorectal peritoneal metastases (PROPHYLOCHIP- NTC01226394).

Diane Goere

3531

REVERCE: Randomized phase II study of regorafenib followed by cetuximab versus the reverse sequence for metastatic colorectal cancer patients previously treated with fluoropyrimidine, oxaliplatin, and irinotecan—Biomarker analysis.

Yasushi Tsuji

3510

Safety analysis of a phase III randomized trial comparing FOLFOX + Bevacizumab vs FOLFOXIRI + Bevacizumab as 1st line treatment in patients with metastatic colorectal cancer (mCRC) with ≥3 circulating tumor cells (CTCs) (VISNÚ-1 TTD TRIAL).

A. Gomez

3536

Safety and tolerability of the bolus 5-fluorouracil (5-FU) based FLOX and IFL regimens in patients who developed fluoropyrimidine-induced coronary vasospasm during therapy with infusional 5-FU or capecitabine.

Sakti Chakrabarti

e15513

Safety of self-expandable metal stents (SEMS) or emergency surgery for acute malignant colonic obstruction in patients treated with bevacizumab.

Vilma Pacheco-Barcia

e15505

Salvage use of Y90 coated hepatic arterial beads in the treatment of liver predominant metastatic colorectal cancer: Cancer Treatment Centers of America Southeastern Region experience.

Eyal Meiri

e15554

Screening and stepped care targeting psychological distress in patients with metastatic colorectal cancer: The TES cluster randomized trial.

Claudia Schuurhuizen

3560

Significance of monitoring vascular endothelial growth factor signals in blood during treatment of colorectal cancer patients.

Nao Kakizawa

e15563

Subgroup analysis by prior anti-VEGF or anti-EGFR target therapy in FRESCO, a randomized, double-blind, phase 3 trial comparing fruquintinib versus placebo plus best supportive care in Chinese patients with metastatic colorectal cancer (mCRC).

Ruihua Xu

3537

Surgical quality and the impact of liver resection on outcome in the New EPOC study.

Sian Alexandra Pugh

3559

The relationship between TACC3 expression and chemotherapy resistance in locally advanced rectal cancer patients.

Rong-xin Zhang

e15512

The trough levels of bevacizumab significantly affect the outcome of the treatment in patients with metastatic colorectal cancer: A Turkish Oncology Group study.

Hakan Akbulut

e15553

Therapeutic and cytotoxic responses after radiofrequency ablation combined to in situ immunomodulation and PD1 blockade in colorectal cancer.

Katia Lemdani

e15562

Treatment of rectal cancer patients with synchronous liver metastases.

Alexey Privalov

e15567

Tumor specific methylation of NPY compared to RAS mutation in plasma DNA in the monitoring of colorectal cancer patients treated with last-line regorafenib.

Lars Henrik Jensen

e15541

Tumoral cavitation in colorectal cancer patients with lung metastasis treated with bevacizumab and chemotherapy.

Hongfeng Gou

e15565

Update survival analysis from a multicenter, randomized phase 3 study on the optimization of the combination of bevacizumab with FOLFOX/OXXEL in patients with metastatic colorectal cancer (mCRC).

Antonio Avallone

3562

Validation of neoadjuvant rectal cancer (NAR) score as a surrogate endpoint for overall survival in real-life practice settings.

Y. Nancy You

3517

What is the prognostic impact of BRAF mutation in patients undergoing resection of colorectal liver metastases? Results of nationwide intergroup (ACHBT, FRENCH, AGEO) cohort of 249 patients.

Jean-Baptiste Bachet

3554